col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Elsevier: Clinical Immunology
  original article Date Title Authors   All Authors
1 [GO] 2022―Jan―19 Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study Mahmoud M. Alseoudy, Mohamed Elgamal, Dalia A. Abdelghany, Asmaa M. Borg, Ahmed El-Mesery, Dina Elzeiny, Maha O. Hammad
2 [GO] 2021―Dec―29 Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring Antonio Cristiano, Massimo Pieri, Serena Sarubbi, Martina Pelagalli, Graziella Calugi, Flaminia Tomassetti, et al. (+2)
3 [GO] 2021―Dec―18 Association of KIR gene polymorphisms with COVID-19 disease Ali Hajeer, Dunia Jawdat, Salam Massadeh, Nora Aljawini, Malak S. Abedalthagafi, Yaseen M. Arabi, Manal Alaamery
4 [GO] 2021―Nov―27 Immunogenicity of SARS-CoV2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters Daniel Magliulo, Stefanie D. Wade, Vasileios C. Kyttaris
5 [GO] 2021―Nov―16 Role of NRF2 and Sirtuin activators in COVID-19 Hasnat Khan, Shivangi Patel, Anuradha Majumdar
6 [GO] 2021―Nov―09 Adult-onset Still's disease following mRNA COVID-19 vaccination Amir Sharabi, Shachaf Shiber, Yair Molad
7 [GO] 2021―Oct―05 Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors Thomas W. Barnes, Johannes Schulte-Pelkum, Laura Steller, Daniel Filchtinski, Robin Jenness, Michelle R. Williams, et al. (+8)
8 [GO] 2021―Sep―30 Commensal bacterial metabolites may strengthen the effect of anti-IL6 treatment for COVID-19 Jiezhong Chen, Luis Vitetta
9 [GO] 2021―Sep―24 A hitchhiker's guide through the COVID-19 galaxy Susanna Felsenstein, Andreas Otto Reiff
10 [GO] 2021―Sep―24 Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey Shirley Shapiro Ben David, Na’ama Shamir-Stein, Sharon Baruch Gez, Uri Lerner, Daniella Rahamim-Cohen, Anat Ekka Zohar
11 [GO] 2021―Sep―22 A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults Junghee J. Shin, Sangchoon Jeon, Serhan Unlu, Jennefer Par-Young, Min Sun Shin, John K. Kuster, et al. (+6)
12 [GO] 2021―Sep―11 Inflammation/coagulopathy/fibrinolysis: Dynamic indicators of COVID-19 progression in patients with moderate COVID-19 in Wenzhou, China Shengwei Jin, Hui An, Tong Zhou, Ting Li, Chengshui Chen, Binyu Ying, et al. (+3)
13 [GO] 2021―Sep―08 Infection with SARS-CoV-2 primes immunological memory in human nasal-associated lymphoid tissue Waleed H. Mahallawi, Talal M. Aljeraisi
14 [GO] 2021―Aug―31 Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year Giuseppe A. Ramirez, Lorenza M. Argolini, Chiara Bellocchi, Luca Moroni, Emanuel Della-Torre, Nicola Farina, et al. (+5)
15 [GO] 2021―Aug―27 Immunomodulation and immunotherapeutics of COVID-19 Sourbh Suren Garg, Atulika Sharma, Jeena Gupta
16 [GO] 2021―Aug―21 Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients Kavita Mathi, Yael Rosenberg-Hasson, Holden Maecker, Dennis J. Carlo, Ronald B. Moss
17 [GO] 2021―Aug―13 Systemic DPP4/CD26 is associated with natural HIV-1 control: Implications for COVID-19 susceptibility Yashini Govender, Sharon Shalekoff, Osman Ebrahim, Ziyaad Waja, Richard E. Chaisson, Neil Martinson, Caroline T. Tiemessen
18 [GO] 2021―Aug―12 COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era A. Deya-Martinez, A. García-García, E.A. Gonzalez-Navarro, L. Yiyi, A. Vlagea, I. Jordan, et al. (+8)
19 [GO] 2021―Aug―04 Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine Miguel García-Grimshaw, Anaclara Michel-Chávez, Juan Mauricio Vera-Zertuche, Javier Andrés Galnares-Olalde, Laura E. Hernández-Vanegas, Melissa Figueroa-Cucurachi, et al. (+6)
20 [GO] 2021―Aug―02 BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review Michael Stack, Keith Sacco, Riccardo Castagnoli, Alicia A. Livinski, Luigi D. Notarangelo, Michail S. Lionakis
21 [GO] 2021―Jul―31 Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection Puya Dehgani-Mobaraki, Asiya Kamber Zaidi, Nidhi Yadav, Alessandro Floridi, Emanuela Floridi
22 [GO] 2021―Jul―23 Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach Ananya Das, Sraddhya Roy, Snehasikta Swarnakar, Nabanita Chatterjee
23 [GO] 2021―Jul―21 COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City Kaoru Harada, Hsi-en Ho, Charlotte Cunningham-Rundles
24 [GO] 2021―Jul―10 Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19 Simin Jamaly, Maria G. Tsokos, Rhea Bhargava, Olga R. Brook, Jonathan L. Hecht, Reza Abdi, et al. (+3)
25 [GO] 2021―Jun―29 Detection of immunoglobulin response to COVID-19 vaccination using a novel rapid fingerstick assay Beth L. Cobb, Amr H. Sawalha
26 [GO] 2021―Jun―29 Severe COVID-19 pneumonia in Good syndrome with a favorable outcome Maria Lourdes Cos Esquius, Inmaculada López Montesinos, Ramón Gimeno Martinez, Jorge Eguía Núñez, M. Araceli Caballero-Rabasco, Blanca Sánchez González, et al. (+2)
27 [GO] 2021―Jun―18 Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study Miguel García-Grimshaw, Santa Elizabeth Ceballos-Liceaga, Laura E. Hernández-Vanegas, Isaac Núñez, Noé Hernández-Valdivia, Daniel Amado Carrillo-García, et al. (+17)
28 [GO] 2021―Jun―09 Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults Kirsi Tamminen, Marjo Salminen, Vesna Blazevic
29 [GO] 2021―Jun―02 Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus Panagiotis A. Ntouros, Nikolaos I. Vlachogiannis, Maria Pappa, Adrianos Nezos, Clio P. Mavragani, Maria G. Tektonidou, et al. (+2)
30 [GO] 2021―Apr―28 IFN-α levels in ruxolitinib-treatead Aicardi-Goutières patient during SARS-CoV-2 infection: A case report Raffaele Badolato, Marco Cattalini, Rosaria Scaduto, Sara Roversi, Jessica Galli, Rosalba Monica Ferraro, et al. (+4)
31 [GO] 2021―Apr―28 Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation Viktorija Erdeljic Turk
32 [GO] 2021―Apr―22 SARS-CoV-2 proteins regulate inflammatory, thrombotic and diabetic responses in human arterial fibroblasts Christopher Thor Freda, Wei Yin, Berhane Ghebrehiwet, David A. Rubenstein
33 [GO] 2021―Apr―19 A novel application of delayed-type hipersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals Yvelise Barrios, Andres Franco, Inmaculada Sanchez-Machin, Paloma Poza-Guedes, Ruperto Gonzalez-Perez, Victor Matheu
34 [GO] 2021―Apr―15 Genetic justification of severe COVID-19 using a rigorous algorithm Eleni Gavriilaki, Panagiotis G. Asteris, Tasoula Touloumenidou, Evaggelia-Evdoxia Koravou, Maria Koutra, Penelope Georgia Papayanni, et al. (+26)
35 [GO] 2021―Apr―09 The microbiota-mediated dietary and nutritional interventions for COVID-19 Amin Gasmi, Torsak Tippairote, Pavan Kumar Mujawdiya, Massimiliano Peana, Alain Menzel, Maryam Dadar, et al. (+2)
36 [GO] 2021―Apr―07 Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products Ariel Kenig, Yuval Ishay, Fadi Kharouf, Limor Rubin
37 [GO] 2021―Apr―03 Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon Karolina Akinosoglou, Ilektra Tzivaki, Markos Marangos
38 [GO] 2021―Apr―02 Serum levels of SARS-CoV-2 nucleocapsid antigen associate with inflammatory status and disease severity in COVID-19 patients Francesco Perna, Sara Bruzzaniti, Erica Piemonte, Valeria Maddaloni, Lidia Atripaldi, Silvia Sale, et al. (+7)
39 [GO] 2021―Mar―24 Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19 Abhigyan Satyam, Maria G. Tsokos, Olga R. Brook, Jonathan L. Hecht, Vaishali R. Moulton, George C. Tsokos
40 [GO] 2021―Mar―07 Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study Meruyert Dauletova, Hafsan Hafsan, Negah Mahhengam, Angelina Olegovna Zekiy, Majid Ahmadi, Homayoon Siahmansouri
41 [GO] 2021―Feb―25 The role of A-to-I RNA editing in infections by RNA viruses: Possible implications for SARS-CoV-2 infection Nikolaos I. Vlachogiannis, Kleio-Maria Verrou, Konstantinos Stellos, Petros P. Sfikakis, Dimitrios Paraskevis
42 [GO] 2021―Feb―21 Coronavirus-induced autoimmunity Valéry Salle
43 [GO] 2021―Feb―16 Temporal viral loads in respiratory and gastrointestinal tract and serum antibody responses during SARS-CoV-2 infection in an Italian pediatric cohort Francesca Caccuri, Antonella Bugatti, Antonella Meini, Carlo Bonfanti, Mario Motta, Lucia Savarè, et al. (+5)
44 [GO] 2021―Feb―05 Common hematological values predict unfavorable outcomes in hospitalized COVID-19 patients Isaac Núñez, Ángel A. Priego-Ranero, H. Benjamín García-González, Brenda Jiménez-Franco, Rebeca Bonilla-Hernández, Guillermo Domínguez-Cherit, et al. (+4)
45 [GO] 2021―Jan―12 Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases” Rossella Talotta
46 [GO] 2021―Jan―09 SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency Nicolai S.C. van Oers, Natasha W. Hanners, Paul Sue, Victor Aquino, Quan-Zhen Li, John W. Schoggins, Christian A. Wysocki
47 [GO] 2020―Dec―16 Interrelations between COVID-19 and other disorders Amin Gasmi, Massimiliano Peana, Lyudmila Pivina, Shvetha Srinath, Asma Gasmi Benahmed, Yuliya Semenova, et al. (+3)
48 [GO] 2020―Dec―16 Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned Varvara A. Ryabkova, Leonid P. Churilov, Yehuda Shoenfeld
49 [GO] 2020―Dec―08 Fatal SARS-CoV-2 infection in a male patient with Good's syndrome Maria Rosa Pozzi, Manuela Baronio, Maria Bianchi Janetti, Luisa Gazzurelli, Daniele Moratto, Marco Chiarini, et al. (+2)
50 [GO] 2020―Dec―07 Kawasaki or Kawasaki-like disease? A debate on COVID-19 infection in children Mohammad-Salar Hosseini
51 [GO] 2020―Nov―28 Peripheral immunological features of COVID-19 patients in Taizhou, China: A retrospective study Xiao-Hong Jin, Hui-Li Zhou, Ling-Ling Chen, Guan-Fu Wang, Qiu-Yue Han, Jian-Gang Zhang, et al. (+5)
52 [GO] 2020―Nov―17 COVID-19: A review of therapeutic strategies and vaccine candidates Vladislav Izda, Matlock A. Jeffries, Amr H. Sawalha
53 [GO] 2020―Nov―13 Major reduction of NKT cells in patients with severe COVID-19 pneumonia Maria Antonella Zingaropoli, Valentina Perri, Patrizia Pasculli, Francesco Cogliati Dezza, Parni Nijhawan, Giulia Savelloni, et al. (+6)
54 [GO] 2020―Nov―12 Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort Hèctor Corominas, Ivan Castellví, Virginia Pomar, Rosa Antonijoan, Isabel Mur, Laia Matas, et al. (+11)
55 [GO] 2020―Oct―27 Commentary on “Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. Isabel Kinney Ferreira de Miranda Santos, Cristina Ribeiro de Barros Cardoso
56 [GO] 2020―Oct―25 Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19 Dimitrios C. Mastellos, John D. Lambris
57 [GO] 2020―Oct―23 Laboratory biomarkers associated with COVID-19 severity and management S. Keddie, O. Ziff, M.K.L. Chou, R.L. Taylor, A. Heslegrave, E. Garr, et al. (+9)
58 [GO] 2020―Oct―23 An enlightening role for cytokine storm in coronavirus infection Zhongyi Zhao, Yinhao Wei, Chuanmin Tao
59 [GO] 2020―Oct―14 Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients Chun Gao, Li Zhu, Cheng Cheng Jin, Yi Xin Tong, Ai Tang Xiao, Sheng Zhang
60 [GO] 2020―Sep―19 Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy Dimitrios C. Mastellos, Bruno G.P. Pires da Silva, Benedito A.L. Fonseca, Natasha P. Fonseca, Maria Auxiliadora-Martins, Sara Mastaglio, et al. (+17)
61 [GO] 2020―Sep―10 On the genetics and immunopathogenesis of COVID-19 Chaim Oscar Jacob
62 [GO] 2020―Sep―06 SARS-CoV-2 infections in children and young people Susanna Felsenstein, Christian M. Hedrich
63 [GO] 2020―Aug―29 Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients María Caridad Montalvo Villalba, Odalys Valdés Ramirez, Mayra Muné Jiménez, Amely Arencibia Garcia, Javier Martinez Alfonso, Guelsy González Baez, et al. (+6)
64 [GO] 2020―Aug―15 Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients Ignacio Iturrieta-Zuazo, Claudia Geraldine Rita, Ana García-Soidán, Ana de Malet Pintos-Fonseca, Nieves Alonso Alarcón, Roberto Pariente Rodríguez, et al. (+4)
65 [GO] 2020―Aug―06 Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 Jeffrey Laurence, J. Justin Mulvey, Madhav Seshadri, Alexandra Racanelli, Joanna Harp, Edward J. Schenck, et al. (+3)
66 [GO] 2020―Jul―31 Critical COVID-19 disease, homeostasis, and the “surprise” of effective glucocorticoid therapy G.P. Chrousos, G.U. Meduri
67 [GO] 2020―Jul―23 Micronutrients as immunomodulatory tools for COVID-19 management Amin Gasmi, Torsak Tippairote, Pavan Kumar Mujawdiya, Massimiliano Peana, Alain Menzel, Maryam Dadar, et al. (+2)
68 [GO] 2020―Jul―22 Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine Homam Ibrahim, Andras Perl, Deane Smith, Tyler Lewis, Zachary Kon, Ronald Goldenberg, et al. (+3)
69 [GO] 2020―Jul―13 mTORC inhibitor Sirolimus deprograms monocytes in “cytokine storm” in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome Claudio Karsulovic, Mercedes Lopez, Fabian Tempio, Julia Guerrero, Annelise Goecke
70 [GO] 2020―Jul―12 Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation? James R. McIlroy, Benjamin H. Mullish, Simon D. Goldenberg, Gianluca Ianiro, Julian R. Marchesi
71 [GO] 2020―Jul―11 Long-term infection of SARS-CoV-2 changed the body's immune status Lan Lin, Shanshan Luo, Renjie Qin, Mengling Yang, Xiaobei Wang, Qianqian Yang, et al. (+8)
72 [GO] 2020―Jun―27 Imatinib for COVID-19: A case report Alejandro Morales-Ortega, David Bernal-Bello, Cristina Llarena-Barroso, Begoña Frutos-Pérez, Miguel Ángel Duarte-Millán, Vanessa García de Viedma-García, et al. (+5)
73 [GO] 2020―Jun―23 Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment Swamy Yeleswaram, Paul Smith, Timothy Burn, Maryanne Covington, Ashish Juvekar, Yanlong Li, et al. (+2)
74 [GO] 2020―Jun―20 COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential Yujie Jiang, Xin Wei, Jingjing Guan, Shuang Qin, Zhongyong Wang, Hong Lu, et al. (+5)
75 [GO] 2020―Jun―13 Development of child immunity in the context of COVID-19 pandemic Małgorzata Kloc, Rafik M. Ghobrial, Ernest Kuchar, Sławomir Lewicki, Jacek Z. Kubiak
76 [GO] 2020―Jun―12 Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy Ciceri Fabio, Castagna Antonella, Rovere-Querini Patrizia, De Cobelli Francesco, Ruggeri Annalisa, Galli Laura, et al. (+27)
77 [GO] 2020―Jun―09 Antibody-dependent enhancement and COVID-19: Moving toward acquittal Eric J. Yager
78 [GO] 2020―Jun―08 A plea for the pathogenic role of immune complexes in severe Covid-19 Dominique A. Vuitton, Lucine Vuitton, Estelle Seillès, Pierre Galanaud
79 [GO] 2020―May―31 Treating COVID-19 with colchicine in community healthcare setting Emanuel Della-Torre, Fabrizio Della-Torre, Marija Kusanovic PCP, Raffaella Scotti, Giuseppe Alvise-Ramirez, Lorenzo Dagna, Moreno Tresoldi
80 [GO] 2020―May―29 Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients J.M. Urra, C.M. Cabrera, L. Porras, I. Ródenas
81 [GO] 2020―May―29 Type 3 hypersensitivity in COVID-19 vasculitis Luca Roncati, Giulia Ligabue, Luca Fabbiani, Claudia Malagoli, Graziana Gallo, Beatrice Lusenti, et al. (+3)
82 [GO] 2020―May―28 Racial disparity in Covid-19 mortality rates - A plausible explanation Yuval Tal, Avner Adini, Alal Eran, Irit Adini
83 [GO] 2020―May―24 Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases Aristo Vojdani, Datis Kharrazianb
84 [GO] 2020―May―21 Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19? Loukman Omarjee, Olivier Meilhac, Frédérique Perrot, Anne Janin, Guillaume Mahe
85 [GO] 2020―May―15 Supplements for COVID-19: A modifiable environmental risk Trevor K. Young, John G. Zampella
86 [GO] 2020―May―13 Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19 Loukman Omarjee, Anne Janin, Frédérique Perrot, Bruno Laviolle, Olivier Meilhac, Guillaume Mahe
87 [GO] 2020―May―11 Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Alan A. Nguyen, Saddiq B. Habiballah, Craig D. Platt, Raif S. Geha, Janet S. Chou, Douglas R. McDonald
88 [GO] 2020―Apr―29 The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 Sara Mastaglio, Annalisa Ruggeri, Antonio M. Risitano, Piera Angelillo, Despina Yancopoulou, Dimitrios C. Mastellos, et al. (+6)
89 [GO] 2020―Apr―27 COVID-19: Immunology and treatment options Susanna Felsenstein, Jenny A. Herbert, Paul S. McNamara, Christian M. Hedrich
90 [GO] 2020―Apr―24 A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection J. Gómez-Rial
91 [GO] 2020―Apr―20 COVID-19 pathophysiology: A review Koichi Yuki, Miho Fujiogi, Sophia Koutsogiannaki
92 [GO] 2020―Apr―18 On the molecular determinants the SARS-CoV-2 attack Darja Kanduc, Yehuda Shoenfeld
93 [GO] 2020―Apr―10 COVID-19 - Considerations for the paediatric rheumatologist Christian M. Hedrich
94 [GO] 2020―Apr―08 COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster Yuanyuan Han, Mao Jiang, Da Xia, Lichao He, Xin Lv, Xiaohua Liao, Jie Meng
95 [GO] 2020―Apr―08 Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients Amr H. Sawalha, Ming Zhao, Patrick Coit, Qianjin Lu
96 [GO] 2020―Apr―07 Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic Amin Gasmi, Sadaf Noor, Torsak Tippairote, Maryam Dadar, Alain Menzel, Geir Bjørklund
97 [GO] 2020―Apr―01 Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 Jie Ma, Peng Xia, Yangzhong Zhou, Zhengyin Liu, Xiang Zhou, Jinglan Wang, et al. (+6)
98 [GO] 2020―Mar―25 The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China Wen Zhang, Yan Zhao, Fengchun Zhang, Qian Wang, Taisheng Li, Zhengyin Liu, et al. (+6)


[de][en]

Last change 2022―Jan―20 20:43:25 UTC

© Daten-Quadrat 2022       Done in 0.016 sec